| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/01/2002 | CA2432988A1 Melanocortin receptor agonists |
| 08/01/2002 | CA2432985A1 Piperazine- and piperidine-derivatives as melanocortin receptor agonists |
| 08/01/2002 | CA2432276A1 Regulation of cell growth by muc1 |
| 08/01/2002 | CA2432134A1 Adenylate cyclases |
| 08/01/2002 | CA2431996A1 Melanocortin receptor agonists |
| 08/01/2002 | CA2431517A1 Polynucleotides encoding cellular transporters and methods of use thereof |
| 08/01/2002 | CA2431493A1 Aminoacyl trna synthetases |
| 08/01/2002 | CA2431313A1 Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators |
| 08/01/2002 | CA2431177A1 Trem-1 splice variant for use in modifying immune responses |
| 08/01/2002 | CA2431144A1 Cell adhesion proteins |
| 08/01/2002 | CA2430743A1 Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses thereof |
| 08/01/2002 | CA2428425A1 Method of treating hematologic tumors and cancers |
| 08/01/2002 | CA2427647A1 Nucleic acid modification enzymes |
| 08/01/2002 | CA2427061A1 Methods and compositions for the identification and treatment of neurodegenerative disorders |
| 08/01/2002 | CA2425506A1 Methods for treating rheumatoid arthritis using il-17 antagonists |
| 07/31/2002 | EP1226864A1 A stable water-in-oil-in-water multiple emulsion system by hydrodynamic dual stabilization and a method for preparation thereof |
| 07/31/2002 | EP1226830A2 Combination therapy involving a sodium-hydrogen exchanger type 1 or NHE-1 inhibitor for use in treatment of ischemia |
| 07/31/2002 | EP1226438A1 Composite nanospheres and their conjugates with biomolecules |
| 07/31/2002 | EP1226435A1 Axor35, a g-protein coupled receptor |
| 07/31/2002 | EP1226433A1 Method for identifying active anti-apoptosis compounds |
| 07/31/2002 | EP1226279A1 Modulation of neuroendocrine differentiation by protein 25.1 |
| 07/31/2002 | EP1226276A2 Diagnostic test for cephalic pain |
| 07/31/2002 | EP1226257A2 Screening and use of agents which block or activate intein splicing utilizing natural or homologous exteins |
| 07/31/2002 | EP1226256A1 Recombinant therapeutic fusion proteins |
| 07/31/2002 | EP1226252A2 DOUBLE-STRANDED RNA RECEPTOR (dsRNA-R) AND METHODS RELATING THERETO |
| 07/31/2002 | EP1226251A2 CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO |
| 07/31/2002 | EP1226250A2 Gpcr-kd5 polypeptides and dna sequences thereof |
| 07/31/2002 | EP1226243A2 Nucleic acid molecules derived from rat brain and programmed cell death models |
| 07/31/2002 | EP1226242A1 Human cub-domain-containing protein and gene encoding the same |
| 07/31/2002 | EP1226237A2 Method of identifying inhibitors of cdc25 |
| 07/31/2002 | EP1226212A1 Polymeric composition for solubilizing poorly water soluble drugs and process for the preparation thereof |
| 07/31/2002 | EP1226177A2 Anti-prostate stem cell antigen (psca) antibody compositions and methods of use |
| 07/31/2002 | EP1226150A1 Tadg-15: an extracellular serine protease overexpressed in carcinomas |
| 07/31/2002 | EP1226136A2 Tyrosine kinase inhibitors |
| 07/31/2002 | EP1226119A2 Tyrosine kinase inhibitors |
| 07/31/2002 | EP1226115A1 Novel carbamates and ureas |
| 07/31/2002 | EP1226109A2 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| 07/31/2002 | EP1226104A1 Phenoxy carboxylic acid compounds and compositions for delivering active agents |
| 07/31/2002 | EP1225956A1 Method and compositions for administering taxanes orally to human patients |
| 07/31/2002 | EP1225921A1 TECHNIQUES AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE BY i IN VIVO /i GENE DELIVERY |
| 07/31/2002 | EP1225919A1 Treatment of cancer |
| 07/31/2002 | EP1225915A2 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 07/31/2002 | EP1225913A1 Use of nitric oxide for the treatment of airway constriction |
| 07/31/2002 | EP1225912A1 A method of prophylaxis and treatment |
| 07/31/2002 | EP1225911A1 Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (mpif-1) |
| 07/31/2002 | EP1225910A2 MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF |
| 07/31/2002 | EP1225909A2 Fibroblast growth factor-5 (fgf-5) is a tumor associated t-cell antigen |
| 07/31/2002 | EP1225904A2 Combinations of lamivudine and entecavir for treatment of hepatitis b virus infection |
| 07/31/2002 | EP1225901A2 Uses and compositions for treating platelet-related disorders using anagrelide |
| 07/31/2002 | EP1225900A1 Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| 07/31/2002 | EP1225899A2 METHOD FOR THE TREATMENT OR PREVENTION OF i FLAVIVIRIDAE /i VIRAL INFECTION USING NUCLEOSIDE ANALOGUES |
| 07/31/2002 | EP1225897A2 Composition for treatment of constipation and irritable bowel syndrome |
| 07/31/2002 | EP1225889A2 Medicament combinations of nifedipine and cerivastatin |
| 07/31/2002 | EP1225884A1 Method for administering a phosphodiesterase 4 inhibitor |
| 07/31/2002 | EP1225881A1 Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction |
| 07/31/2002 | EP1225880A2 Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders |
| 07/31/2002 | EP1225878A1 Treatment of emphysema using rar selective retinold agonists |
| 07/31/2002 | EP1225877A2 Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis |
| 07/31/2002 | EP1225866A2 Method and compositions for treating pulmonary diseases |
| 07/31/2002 | EP1225814A1 Fibrous-liponutritional complexes and compositions containing them |
| 07/31/2002 | EP1225809A2 Methods for stabilizing liquid nutritional products and products so stabilized |
| 07/31/2002 | EP1137414A4 Use of acetylcholinesterase inhibitors on the modulation of the hypothalamic-pituitary-gonadal axis |
| 07/31/2002 | EP1049490B1 Method for inhibiting cd95-independent apoptosis in aids |
| 07/31/2002 | EP0825848B1 Translucent collagen formulations |
| 07/31/2002 | EP0760650B1 Antimicrobial oil-in-water emulsions |
| 07/31/2002 | EP0583356B1 A method for treating infectious respiratory diseases |
| 07/31/2002 | CN1361865A Catalytic anti-factor VIII allo-antibodies |
| 07/31/2002 | CN1361789A Rapid dehydration of proteins |
| 07/31/2002 | CN1361774A Heterocyclic substituted aminoazacycles useful as central nervous system agents |
| 07/31/2002 | CN1361765A Inhibitors of aspartyl protease |
| 07/31/2002 | CN1361763A Aminobenzophenones as inhibitors of IL-1 beta and TNF_alpha |
| 07/31/2002 | CN1361700A Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
| 07/31/2002 | CN1361693A Use of 1,4-benzothiazepine derivatives as drugs overcoming carcinostatic tolerance |
| 07/31/2002 | CN1361686A Percutaneously absorbable preparations |
| 07/31/2002 | CN1361683A Novel preparation and administration form comprising an acid-labile active compound |
| 07/31/2002 | CN1361681A Methods for preparation of lipid-encapsulated therapeutic agents |
| 07/31/2002 | CN1361680A Use of at least one extract of aplant of the genus lannea in a cosmetic or dermopharmaceutical composition |
| 07/31/2002 | CN1361677A Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| 07/31/2002 | CN1088361C Combined use of diclofenac and tribenoside to treat osteoarthritis |
| 07/31/2002 | CN1088359C Medicine for curing cerebrovascular disturbance with psychonosema |
| 07/31/2002 | CN1088358C Antitussive composition containing antitussive and benzydamine |
| 07/31/2002 | CA2369462A1 Nicotinamide acids, amides, and their mimetics active as inhibitors of pde4 isozymes |
| 07/30/2002 | US6426405 Therapeutic target for treatment of diseases associated with altered muscle activity of pain transmission; has properties of glycine transporter associated with strychnine sensitive glycine receptors--properties called ?sc6? activity |
| 07/30/2002 | US6426368 Method for preventing and treating alcoholism |
| 07/30/2002 | US6426367 Methods for selectively occluding blood supplies to neoplasias |
| 07/30/2002 | US6426362 Formulations of tocopherols and methods of making and using them |
| 07/30/2002 | US6426359 Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonists |
| 07/30/2002 | US6426358 Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma |
| 07/30/2002 | US6426351 Administering in combination with chemotherapeutic agents that directly damage dna; extremely cytotoxic |
| 07/30/2002 | US6426343 Preparation and use of a specific GABA-Aα5 receptor ligand for treatment of Alzheimer's disease |
| 07/30/2002 | US6426342 Clavulanic acid, salts or esters along with a carrier for controlled release |
| 07/30/2002 | US6426341 Treatment for diabetic complications |
| 07/30/2002 | US6426339 In situ; sustained release; preadministering glucocorticosteroid |
| 07/30/2002 | US6426217 MAGE-3 peptides presented by HLA class II molecules |
| 07/30/2002 | US6426199 Isolated, purified nucleic acid detecting or isolating mutant forms of the dna molecules. |
| 07/30/2002 | US6426099 Herbal formulation for rebuilding intestinal bacteria |
| 07/30/2002 | US6426094 Method of enhancing the efficacy of anti-tumor agents |
| 07/30/2002 | US6426085 Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis |
| 07/30/2002 | US6426069 Method and compositions for increasing intestinal absorption of fats |
| 07/30/2002 | US6425881 Therapeutic mixture useful in inhibiting lesion formation after vascular injury |